Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1998-04-09
2000-01-11
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
424 932, 4241861, 4241921, 4241991, 435 6, 435 29, 435 691, 435 697, 43525233, 4353171, 4353201, 435325, A61K 39085, A61K 3912, A61K 3900, A01N 6300
Patent
active
060132663
ABSTRACT:
The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagonostic tests for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strain and vaccine strains.
REFERENCES:
Timothy J. Anderson, Thesis, University of Guelph, Nov. 1995, Characterization of the LACZ, GALK, and GALM Genes of Actinobacilus Pleuropneumoniae.
Anderson et al. 1991. Isolation and Molecular characterization of Spontaneously Occuring Cytolysin-Negative Mutants of Actinobacillus pleuropneumoniae Serotypre 7. Infection and Immunity. 59 (11): 4110-4116.
Frey, J. 1995, Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends in Microbiology. 3(7): 257-261.
Jansen et al. 1995. Knockout Mutants of Actinobcillus pleuropneumoniae Serotype 1 That Are Devoid of RTX Toxins Do Not activate or Kill Porcine Neutrophils. Infection and Immunity. 63(1):27-37.
Michalski, J. et al. 1993. CVD110, an Attenuated Vibrio cholerae 01 E1 Tor Live Oral vaccine Strain. Infection and Immunity. 61(10):4462-4468.
Rosendal et al. 1990. Characterization of an attenuated strain of Actinobacillus pleuropneumoniae, serotype 1. American Journal of Veterinary Research. 51(5): 711-717.
Tascon et al. 1994. The RTX haemolysins ApxI and ApxII are major virulence factors of the swine pathogen Actinobacillus pleuropneumoniae: evidence from mutational analysis. Molecular Microbiology. 14(2): 207-216.
Frey et al., Schweizer Archiv Fur Tierheilkunde, 138:3:121-124, 1996.
Frey Joachim
Segers Ruud Philip Antoon Maria
Akzo Nobel N.V.
Gormley Mary E.
Hines Ja'Na
Housel James C.
LandOfFree
Live attenuated bacteria of the species Actinobacillus pleuropne does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live attenuated bacteria of the species Actinobacillus pleuropne, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live attenuated bacteria of the species Actinobacillus pleuropne will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459952